This webinar was held on Thursday October 22nd 2020
and is available for healthcare professionals to watch below

Care of the cardiorenal patient:

a focus on RAAS inhibition and management of hyperkalaemia

This webinar is supported by Vifor Pharma UK with an unrestricted educational grant.

What is the webinar about?

We have been listening to your feedback that you would like more case-based and practical learning so we are delighted to be able offer this new webinar, led by experts in the field, that will discuss the practical approach to the management of hyperkalaemia in patients with cardiorenal disease.

This will include the approach to broad-spectrum presentations, from those with potentially life-threatening hyperkalaemia through to the impact of high potassium on the use of prognostically important renin-angiotensin-aldosterone system (RAAS) inhibitors. Using case examples, they will discuss and guide on how to optimally manage such patients and avoid pitfalls that might have adverse consequences. Wherever possible, local pathways will be used and multidisciplinary discussion encouraged.

Learning objectives

At the end of the webinar, delegates will have learned/contributed to multidisciplinary discussion around the following topics:

  • The prevalence of hyperkalaemia, its potential causes, presentation, and association with adverse outcomes
  • The prognostic benefit of RAAS inhibitors in patients with chronic heart failure and those with CKD and how hyperkalaemia may influence their prescription
  • The role of potassium binders in managing acute hyperkalaemia and facilitating the use of RAAS inhibitors
  • What guidelines say
  • Review of local guidelines – are they contemporary?
  • Practical advice on how to manage hyperkalaemia in hospital and in the community
  • Multidisciplinary discussion around case histories including special groups, and clinical questions

Is it for me?

This webinar is intended for healthcare professionals. It is aimed at anyone treating the cardiorenal patient particularly those working in heart failure, cardiology, nephrology, care of the elderly, general medicine, general practitioners, clinical pharmacists and allied disciplines.

Accreditation

The Royal College of Physicians have endorsed this webinar for 2 CPD points. Participants accessing this archived version of the webinar may record this in their CPD diary using the approval code 133114 for up to four weeks after the live event (i.e. up to 19 November 2020).

Endorsements

We are delighted that KDIGO (Kidney Disease Improving Global Outcomes) has endorsed this webinar.

Programme
  • 00:00:00   Introduction by Chair, Professor Paul Kalra, Consultant Cardiologist, Portsmouth Hospitals NHS Trust
  • 00:04:48   The importance of potassium homeostasis in cardiorenal patients
    Professor Philip Kalra, Consultant Nephrologist, Salford Royal NHS Foundation Trust; Professor of Renal Medicine, University of Manchester
  • 00:30:52   Treating hyperkalaemia to protect the kidney
    Dr Kieran McCafferty, Consultant Nephrologist, Barts Health NHS Trust; Senior Lecturer, Queen Mary University London
  • 00:51:44   Treating hyperkalaemia to optimise heart failure treatment
    Dr Patricia Campbell, Consultant Cardiologist and Heart Failure Clinical Lead, Southern Health and Social Care Trust, Northern Ireland
  • 01:16:23   Discussion with a nursing and pharmacy perspective
    Ms Carys Barton, Heart Failure Specialist Nurse Consultant, Imperial College Healthcare NHS Trust
    Ms Janine Beezer, Advanced Clinical Pharmacist (heart failure), South Tyneside and Sunderland Foundation Trust; Visiting Researcher, Newcastle University
  • 01:52:00   Webinar close

  • We are able to provide this webinar free of charge for health care professionals. This webinar is supported by Vifor Pharma UK with an unrestricted educational grant.
   
Faculty

Ms Carys Barton Heart Failure Nurse Consultant, Imperial College Healthcare NHS Trust

Carys Barton is a Heart Failure Nurse Consultant at Imperial College Healthcare Trust, London, and current chair of the British Society for Heart Failure nurse forum. She is an experienced heart failure specialist nurse with wide experience across cardiology, with a special interest in palliative care in heart failure. She is committed to supporting the development and education of specialist heart failure nurses.

Ms Janine Beezer Advanced Clinical Pharmacist (heart failure), South Tyneside and Sunderland Foundation Trust; Visiting Researcher, Newcastle University

Janine Beezer has worked within the inpatient heart failure service for the last eight years managing heart failure patients throughout their inpatient journey and on discharge. She is particularly interested in the care of older heart failure patients and the impact of frailty. She is a Fellow of the Royal Pharmaceutical Society, board member of the British Society for Heart Failure, a member of the National Heart Failure Audit domain expert group, and a founding member of the UK Clinical Pharmacists’ Association heart failure group.

Dr Patricia Campbell Consultant Cardiologist and Heart Failure Clinical Lead, Southern Health and Social Care Trust, Northern Ireland

Patricia Campbell is a graduate of University College Dublin (UCD) and undertook residency training between Ireland and the Mayo Clinic, Scottsdale, USA. She also undertook heart failure and echo training at the Brigham & Women's Hospital, Harvard Medical School, Boston, USA, and was Assistant Professor at the University of Calgary and UCD, before coming finally home to take up role as heart failure lead in Southern Trust, Northern Ireland.

Professor Paul Kalra Consultant Cardiologist, Portsmouth Hospitals NHS Trust

Paul Kalra is a Consultant Cardiologist at Portsmouth Hospitals NHS Trust, and an Honorary Professor of Cardiology. His research interests include the role of iron deficiency and its correction in patients with heart failure, cardiorenal disease and the impact of hyperkalaemia on RAAS inhibition use. He is one of the founders of the Cardiorenal Forum and past Chair of the British Society for Heart Failure.

Professor Philip Kalra Consultant Nephrologist, Salford Royal NHS Foundation Trust; Professor of Renal Medicine, University of Manchester

Philip Kalra graduated from Cambridge University and is Professor of Nephrology in Salford and the University of Manchester. He has been a Consultant Nephrologist since 1995, working at the Salford Royal NHS Foundation Trust. He has major research focus on renovascular disease, cardiovascular disease in chronic kidney disease (CKD), CKD progression and iron use in CKD, and he leads the research team in Salford. He was Academic Vice President of the UK Renal Association from 2016–19, Chair of the UK Kidney Research Consortium during this time and was Chair of the NIHR CRN Renal Disorders group from 2010–18. He has been involved in the development of several large UK clinical trials in nephrology and cardiology, including the ASTRAL, PIVOTAL and IRONMAN trials, and he has played a role in amalgamating Cardiorenal education and research within the UK.

Dr Kieran McCafferty Consultant Nephrologist, Barts Health NHS Trust and Senior Lecturer, Queen Mary University London

Kieran McCafferty is a Consultant Nephrologist at Barts Health NHS Trust and Senior Lecturer and Queen Mary University London. His main clinical interests are diabetic kidney disease and haemodialysis. His basic science research interests are in the field of uraemic cardiovascular disease and cardiovascular protection. However he spends most of his research time developing and delivering clinical trials at both a local and national level.

 

Funding

This webinar is supported by Vifor Pharma UK with an unrestricted educational grant.